Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 163

1.

Nanoparticulate vaccine inhibits tumor growth via improved T cell recruitment into melanoma and huHER2 breast cancer.

Zupančič E, Curato C, Kim JS, Yeini E, Porat Z, Viana AS, Globerson-Levin A, Waks T, Eshhar Z, Moreira JN, Satchi-Fainaro R, Eisenbach L, Jung S, Florindo HF.

Nanomedicine. 2018 Apr;14(3):835-847. doi: 10.1016/j.nano.2017.12.011. Epub 2018 Jan 3.

PMID:
29306001
2.

Therapeutic Potential of T Cell Chimeric Antigen Receptors (CARs) in Cancer Treatment: Counteracting Off-Tumor Toxicities for Safe CAR T Cell Therapy.

Gross G, Eshhar Z.

Annu Rev Pharmacol Toxicol. 2016;56:59-83. doi: 10.1146/annurev-pharmtox-010814-124844. Review.

PMID:
26738472
3.

Functional comparison of engineered T cells carrying a native TCR versus TCR-like antibody-based chimeric antigen receptors indicates affinity/avidity thresholds.

Oren R, Hod-Marco M, Haus-Cohen M, Thomas S, Blat D, Duvshani N, Denkberg G, Elbaz Y, Benchetrit F, Eshhar Z, Stauss H, Reiter Y.

J Immunol. 2014 Dec 1;193(11):5733-43. doi: 10.4049/jimmunol.1301769. Epub 2014 Oct 31.

4.

From the mouse cage to human therapy: a personal perspective of the emergence of T-bodies/chimeric antigen receptor T cells.

Eshhar Z.

Hum Gene Ther. 2014 Sep;25(9):773-8. doi: 10.1089/hum.2014.2532. No abstract available.

5.

Suppression of murine colitis and its associated cancer by carcinoembryonic antigen-specific regulatory T cells.

Blat D, Zigmond E, Alteber Z, Waks T, Eshhar Z.

Mol Ther. 2014 May;22(5):1018-28. doi: 10.1038/mt.2014.41. Epub 2014 Mar 6.

6.

The emergence of T-bodies/CAR T cells.

Eshhar Z, Waks T, Gross G.

Cancer J. 2014 Mar-Apr;20(2):123-6. doi: 10.1097/PPO.0000000000000027. Review.

PMID:
24667957
7.

Allogeneic chimeric antigen receptor-modified cells for adoptive cell therapy of cancer.

Marcus A, Eshhar Z.

Expert Opin Biol Ther. 2014 Jul;14(7):947-54. doi: 10.1517/14712598.2014.900540. Epub 2014 Mar 24. Review.

PMID:
24661086
8.

Elimination of progressive mammary cancer by repeated administrations of chimeric antigen receptor-modified T cells.

Globerson-Levin A, Waks T, Eshhar Z.

Mol Ther. 2014 May;22(5):1029-38. doi: 10.1038/mt.2014.28. Epub 2014 Feb 27.

9.

CAR's made it to the pancreas.

Chmielewski M, Maliar A, Eshhar Z, Abken H.

Oncoimmunology. 2012 Nov 1;1(8):1387-1389.

10.

Mixed alkanethiol monolayers on submicrometric gold patterns: a controlled platform for studying cell-ligand interactions.

Fishler R, Artzy-Schnirman A, Peer E, Wolchinsky R, Brener R, Waks T, Eshhar Z, Reiter Y, Sivan U.

Nano Lett. 2012 Sep 12;12(9):4992-6. doi: 10.1021/nl302619p. Epub 2012 Aug 21.

PMID:
22900991
11.

Redirected T cells that target pancreatic adenocarcinoma antigens eliminate tumors and metastases in mice.

Maliar A, Servais C, Waks T, Chmielewski M, Lavy R, Altevogt P, Abken H, Eshhar Z.

Gastroenterology. 2012 Nov;143(5):1375-1384.e5. doi: 10.1053/j.gastro.2012.07.017. Epub 2012 Jul 20.

PMID:
22819865
12.

Tumor-specific allogeneic cells for cancer therapy.

Marcus A, Eshhar Z.

Expert Opin Biol Ther. 2011 Dec;11(12):1551-4. doi: 10.1517/14712598.2011.628934. Epub 2011 Oct 14.

PMID:
21995504
13.

Electrically controlled molecular recognition harnessed to activate a cellular response.

Artzy-Schnirman A, Blat D, Talmon Y, Fishler R, Gertman D, Oren R, Wolchinsky R, Waks T, Benhar I, Eshhar Z, Sivan U, Reiter Y.

Nano Lett. 2011 Nov 9;11(11):4997-5001. doi: 10.1021/nl202971r. Epub 2011 Oct 21.

PMID:
21985491
14.

Allogeneic adoptive cell transfer therapy as a potent universal treatment for cancer.

Marcus A, Eshhar Z.

Oncotarget. 2011 Jul;2(7):525-6. No abstract available.

15.

Redirected tumor-specific allogeneic T cells for universal treatment of cancer.

Marcus A, Waks T, Eshhar Z.

Blood. 2011 Jul 28;118(4):975-83. doi: 10.1182/blood-2011-02-334284. Epub 2011 Jun 7.

PMID:
21653325
16.

Development of adoptive cell therapy for cancer: a clinical perspective.

Hawkins RE, Gilham DE, Debets R, Eshhar Z, Taylor N, Abken H, Schumacher TN, ATTACK Consortium.

Hum Gene Ther. 2010 Jun;21(6):665-72. doi: 10.1089/hum.2010.086. Review.

PMID:
20408760
17.
18.

A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity.

Zhao Y, Wang QJ, Yang S, Kochenderfer JN, Zheng Z, Zhong X, Sadelain M, Eshhar Z, Rosenberg SA, Morgan RA.

J Immunol. 2009 Nov 1;183(9):5563-74. doi: 10.4049/jimmunol.0900447.

19.

Interspecies comparison of prostate cancer gene-expression profiles reveals genes associated with aggressive tumors.

Kela I, Harmelin A, Waks T, Orr-Urtreger A, Domany E, Eshhar Z.

Prostate. 2009 Jul 1;69(10):1034-44. doi: 10.1002/pros.20950.

PMID:
19343735
20.

Amelioration of colitis by genetically engineered murine regulatory T cells redirected by antigen-specific chimeric receptor.

Elinav E, Adam N, Waks T, Eshhar Z.

Gastroenterology. 2009 May;136(5):1721-31. doi: 10.1053/j.gastro.2009.01.049. Epub 2009 Jan 27.

PMID:
19208357
21.

Redirection of regulatory T cells with predetermined specificity for the treatment of experimental colitis in mice.

Elinav E, Waks T, Eshhar Z.

Gastroenterology. 2008 Jun;134(7):2014-24. doi: 10.1053/j.gastro.2008.02.060. Epub 2008 Mar 4.

PMID:
18424268
22.

Irradiation enhances the metastatic potential of prostatic small cell carcinoma xenografts.

Agemy L, Harmelin A, Waks T, Leibovitch I, Rabin T, Pfeffer MR, Eshhar Z.

Prostate. 2008 Apr 1;68(5):530-9. doi: 10.1002/pros.20702.

PMID:
18247403
23.

The T-body approach: redirecting T cells with antibody specificity.

Eshhar Z.

Handb Exp Pharmacol. 2008;(181):329-42. Review.

PMID:
18071952
24.

A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer.

Kershaw MH, Westwood JA, Parker LL, Wang G, Eshhar Z, Mavroukakis SA, White DE, Wunderlich JR, Canevari S, Rogers-Freezer L, Chen CC, Yang JC, Rosenberg SA, Hwu P.

Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6106-15.

25.
27.

Redirected primary T cells harboring a chimeric receptor require costimulation for their antigen-specific activation.

Friedmann-Morvinski D, Bendavid A, Waks T, Schindler D, Eshhar Z.

Blood. 2005 Apr 15;105(8):3087-93. Epub 2004 Dec 30.

PMID:
15626734
28.

Epigen, the last ligand of ErbB receptors, reveals intricate relationships between affinity and mitogenicity.

Kochupurakkal BS, Harari D, Di-Segni A, Maik-Rachline G, Lyass L, Gur G, Kerber G, Citri A, Lavi S, Eilam R, Chalifa-Caspi V, Eshhar Z, Pikarsky E, Pinkas-Kramarski R, Bacus SS, Yarden Y.

J Biol Chem. 2005 Mar 4;280(9):8503-12. Epub 2004 Dec 17.

29.

Adoptive immunotherapy of prostate cancer bone lesions using redirected effector lymphocytes.

Pinthus JH, Waks T, Malina V, Kaufman-Francis K, Harmelin A, Aizenberg I, Kanety H, Ramon J, Eshhar Z.

J Clin Invest. 2004 Dec;114(12):1774-81.

30.

ErbB2 is a tumor associated antigen and a suitable therapeutic target in Wilms tumor.

Pinthus JH, Fridman E, Dekel B, Goldberg I, Kaufman-Francis K, Eshhar Z, Harmelin A, Rechavi G, Mor O, Ramon J, Mor Y.

J Urol. 2004 Oct;172(4 Pt 2):1644-8.

PMID:
15371781
32.

Photodynamic therapy of established prostatic adenocarcinoma with TOOKAD: a biphasic apparent diffusion coefficient change as potential early MRI response marker.

Plaks V, Koudinova N, Nevo U, Pinthus JH, Kanety H, Eshhar Z, Ramon J, Scherz A, Neeman M, Salomon Y.

Neoplasia. 2004 May-Jun;6(3):224-33.

33.

Immuno-gene therapy of established prostate tumors using chimeric receptor-redirected human lymphocytes.

Pinthus JH, Waks T, Kaufman-Francis K, Schindler DG, Harmelin A, Kanety H, Ramon J, Eshhar Z.

Cancer Res. 2003 May 15;63(10):2470-6.

34.

Quantitative detection of protein arrays.

Levit-Binnun N, Lindner AB, Zik O, Eshhar Z, Moses E.

Anal Chem. 2003 Mar 15;75(6):1436-41.

PMID:
12659207
35.

Photodynamic therapy with Pd-Bacteriopheophorbide (TOOKAD): successful in vivo treatment of human prostatic small cell carcinoma xenografts.

Koudinova NV, Pinthus JH, Brandis A, Brenner O, Bendel P, Ramon J, Eshhar Z, Scherz A, Salomon Y.

Int J Cancer. 2003 May 10;104(6):782-9.

36.

Opinion paper on the current status of the regulation of gene therapy in Europe.

Cohen-Haguenauer O, Rosenthal F, Gänsbacher B, Bolhuis R, Dorsch-Häsler K, Eshhar Z, Gahrton G, Hokland P, Melani C, Rankin E, Thielemans K, Vile R, Zwierzina H, Cichutek K; Euregenethy Network.

Hum Gene Ther. 2002 Nov 20;13(17):2085-110. No abstract available.

PMID:
12490003
37.

Multiple genes in human 20q13 chromosomal region are involved in an advanced prostate cancer xenograft.

Bar-Shira A, Pinthus JH, Rozovsky U, Goldstein M, Sellers WR, Yaron Y, Eshhar Z, Orr-Urtreger A.

Cancer Res. 2002 Dec 1;62(23):6803-7.

38.

Esterolytic antibodies as mechanistic and structural models of hydrolases-a quantitative analysis.

Lindner AB, Kim SH, Schindler DG, Eshhar Z, Tawfik DS.

J Mol Biol. 2002 Jul 12;320(3):559-72.

PMID:
12096909
39.

Growth inhibition of prostate cancer xenografts by halofuginone.

Gavish Z, Pinthus JH, Barak V, Ramon J, Nagler A, Eshhar Z, Pines M.

Prostate. 2002 May 1;51(2):73-83.

PMID:
11948962
40.

Unusual alternative splicing within the human kallikrein genes KLK2 and KLK3 gives rise to novel prostate-specific proteins.

David A, Mabjeesh N, Azar I, Biton S, Engel S, Bernstein J, Romano J, Avidor Y, Waks T, Eshhar Z, Langer SZ, Lifschitz-Mercer B, Matzkin H, Rotman G, Toporik A, Savitsky K, Mintz L.

J Biol Chem. 2002 May 17;277(20):18084-90. Epub 2002 Feb 7.

41.

T-bodies as antiviral agents.

Bitton N, Debre P, Eshhar Z, Gorochov G.

Curr Top Microbiol Immunol. 2001;260:271-300. Review. No abstract available.

PMID:
11443878
42.

Functional expression of chimeric receptor genes in human T cells.

Eshhar Z, Waks T, Bendavid A, Schindler DG.

J Immunol Methods. 2001 Feb 1;248(1-2):67-76.

PMID:
11223069
43.

WISH-PC2: a unique xenograft model of human prostatic small cell carcinoma.

Pinthus JH, Waks T, Schindler DG, Harmelin A, Said JW, Belldegrun A, Ramon J, Eshhar Z.

Cancer Res. 2000 Dec 1;60(23):6563-7.

44.

Grafting primary human T lymphocytes with cancer-specific chimeric single chain and two chain TCR.

Willemsen RA, Weijtens ME, Ronteltap C, Eshhar Z, Gratama JW, Chames P, Bolhuis RL.

Gene Ther. 2000 Aug;7(16):1369-77.

45.

Tyrosine kinase chimeras for antigen-selective T-body therapy.

Eshhar Z, Fitzer-Attas CJ.

Adv Drug Deliv Rev. 1998 Apr 6;31(1-2):171-182.

PMID:
10837624
46.

Recognition of human colon cancer by T cells transduced with a chimeric receptor gene.

Daly T, Royal RE, Kershaw MH, Treisman J, Wang G, Li W, Herlyn D, Eshhar Z, Hwu P.

Cancer Gene Ther. 2000 Feb;7(2):284-91.

47.
48.

Transfer of chimeric receptor gene made of variable regions of tumor-specific antibody confers anticarbohydrate specificity on T cells.

Mezzanzanica D, Canevari S, Mazzoni A, Figini M, Colnaghi MI, Waks T, Schindler DG, Eshhar Z.

Cancer Gene Ther. 1998 Nov-Dec;5(6):401-7.

PMID:
9917095
49.

Conformational changes affect binding and catalysis by ester-hydrolysing antibodies.

Lindner AB, Eshhar Z, Tawfik DS.

J Mol Biol. 1999 Jan 8;285(1):421-30.

PMID:
9878416

Supplemental Content

Loading ...
Support Center